Acutaas Chemicals Ltd logo

Acutaas Chemicals Ltd

ACUTAAS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹26,304 Cr
Volatility
Moderate
P/E Ratio
71.9
EBITDA
₹480 Cr
Return on Equity
12.15%
Debt to Equity
0.02
Book Value
₹201.97
EPS
₹15.13
52W High
₹3,740
52W Low
₹1,302

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Acutaas Chemicals Ltd insights

63 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 15.8 times its book value
  • Promoter holding has decreased over last 3 years: -6.75%

Growth Rate

Revenue Growth
30.82% ↗
Net Income Growth
127.89% ↗
Cash Flow Change
-5.46% ↘
ROE
70.41% ↗
ROCE
52.45% ↗
EBITDA Margin (Avg.)
43.05% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk high

Acutaas Chemicals Ltd is a small-cap healthcare/chemicals company with a market cap of ₹26,053 Cr, trading at a PE of 66.6x and PB of 15.6x. The company has delivered strong profit growth of 104% TTM and 62% CAGR over 3 years, while remaining almost debt-free, though promoter holding has declined by 6.75% over three years.

Bull Case 8
  • Company is almost debt-free, providing financial flexibility and low interest burden
  • Compounded profit growth of 104% TTM indicates sharp acceleration in earnings
  • 5-year compounded profit CAGR of 46% demonstrates sustained long-term earnings momentum
  • 3-year compounded sales growth of 30% shows consistent top-line expansion
  • TTM sales growth of 41% indicates accelerating revenue trajectory compared to 3-year average of 30%
  • ROE improved to 24% in the last year from 18% over 3-year and 5-year averages, showing improving capital efficiency
  • Stock price CAGR of 139% over 1 year and 69% over 3 years reflects strong market re-rating
  • Company is expected to deliver a good upcoming quarter based on available estimates
Bear Case 8
  • PE ratio of 66.6x is significantly elevated, pricing in substantial future growth
  • Stock trades at 15.6x book value, indicating expensive valuation relative to net assets
  • Promoter holding has decreased by 6.75% over the last 3 years, signaling potential insider confidence concerns
  • Dividend yield of just 0.05% offers negligible income return to shareholders
  • 10-year ROE of 20% versus last year's 24% suggests current profitability may be near a cyclical peak rather than structural improvement
  • Key financial metrics like debt-to-equity, EPS, and ROCE are unavailable, limiting comprehensive fundamental analysis
  • 52-week high and low data showing 0 suggests limited price discovery transparency or recent listing
  • Small market cap of ₹26,053 Cr combined with rich valuations increases vulnerability to sharp corrections in risk-off environments

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Positives 3
  • Q1 profit surges 70% YoY Jul 28

    Net profit jumped 70% to ₹74.9-75.9 crore in Q1 FY27, with revenue rising 47-59% YoY to ₹327-330 crore driven by pharma intermediates and new battery chemical supplies.

  • 25% revenue growth guided FY27 Jul 27

    Management guided 25% revenue growth for FY27 with stable margins, targeting INR 1,000 crore in CDMO revenue backed by 30-40 new molecules developed annually.

  • Battery chemicals ramp-up begins Jul 27

    Battery chemicals supply has commenced with rapid volume increase expected in coming quarters. The 4,000 MT plant targets 100% capacity utilisation within three years.

Neutral 3
  • Investor meets in Aug Aug 8

    Acutaas Chemicals officials will attend investor conferences in Singapore and Mumbai on August 12-13, 2026 for one-on-one and group meetings.

  • Q1 earnings call hosted Jul 20

    Q1FY27 results discussed on July 24, 2026 conference call hosted by Nuvama Wealth Management. Recording made available on company website per SEBI regulations.

  • Board approves Q1 results Jul 24

    Board approved unaudited standalone and consolidated Q1FY26 financial results on July 24, 2026, reviewed by Audit Committee and statutory auditors.

TL;DR: Acutaas Chemicals delivered a strong Q1 with 70% profit growth and nearly 50-60% revenue expansion, signaling robust execution. Management has guided 25% revenue growth for FY27 with new growth vectors in battery chemicals and CDMO. No visible headwinds in recent news flow, though commodity chemical weakness was flagged as a partial offset. The trend is clearly improving with multiple growth levers activating simultaneously.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
154
172
166
225
177
247
275
308
207
306
393
433
330
Expenses
120
148
140
182
147
198
206
224
156
211
243
249
217
Operating Profit
34
25
27
43
30
49
69
85
51
95
151
184
113
OPM %
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
34%
Other Income
1
-30
3
1
1
8
2
6
16
10
5
11
2
Interest
1
1
3
2
4
0
1
1
1
1
1
1
1
Depreciation
4
4
4
5
6
7
6
7
8
8
10
10
10
PBT
31
-10
24
37
20
50
63
83
58
96
145
184
104
Tax %
28%
71%
25%
31%
26%
25%
28%
24%
24%
25%
27%
27%
28%
Net Profit
22
-17
18
26
15
38
45
63
44
72
106
134
75
EPS in Rs
2.71
-2.55
2.27
3.41
1.71
4.56
5.49
7.63
5.41
8.82
13.19
16.09
9.07
Figures in ₹ Crores

Profit & Loss

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
160
188
239
240
341
520
617
717
1,007
1,339
1,462
Expenses
137
157
196
198
260
415
493
589
775
859
919
Operating Profit
23
31
42
42
80
105
123
128
232
480
543
OPM %
14%
16%
18%
17%
24%
20%
20%
18%
23%
36%
37%
Other Income
0
3
0
2
1
3
4
-25
17
42
27
Interest
3
3
5
6
6
6
2
6
6
3
4
Depreciation
1
2
3
4
4
10
12
16
27
36
38
PBT
19
28
35
35
72
91
112
82
216
483
529
Tax %
35%
35%
34%
21%
25%
21%
26%
41%
26%
26%
—
Net Profit
12
18
23
27
54
72
83
49
160
356
387
EPS in Rs
40.17
61.67
11.1
13.08
8.57
9.87
11.43
5.8
19.38
43.51
47.17
Div. Payout %
0%
0%
0%
0%
0%
15%
13%
26%
8%
6%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
10
10
32
36
36
37
41
41
Reserves
37
56
72
101
135
486
558
637
1,269
1,613
Borrowings
27
44
54
59
137
1
4
217
13
36
Other Liabilities
43
54
77
61
110
136
169
205
227
295
Total Liabilities
109
155
213
232
413
659
767
1,096
1,549
1,984
Fixed Assets
28
32
79
85
186
205
259
427
570
745
CWIP
11
30
2
12
0
3
30
125
130
332
Investments
1
3
2
2
1
2
2
0
0
0
Other Assets
68
91
131
133
225
450
477
543
848
907
Total Assets
109
155
213
232
413
659
767
1,096
1,549
1,984
Figures in ₹ Crores

Cash Flow

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
29
8
15
27
28
-12
66
125
118
292
Investing
-19
-25
-21
-24
-101
-121
-33
-365
-224
-266
Financing
-7
15
6
0
72
140
-12
239
261
4
Net Cash Flow
3
-2
0
3
-1
8
20
-1
156
30
Free Cash Flow
10
-16
-7
6
-77
-46
-31
-155
-76
-36
CFO/OP
153
53
68
85
52
10
73
116
71
84
Figures in ₹ Crores

Ratios

  Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
97
116
86
129
115
136
105
105
99
Inventory Days
76
89
95
148
123
150
131
139
119
149
Days Payable
148
154
168
146
172
158
157
119
103
99
Cash Conversion Cycle
11
31
43
88
80
107
111
125
121
149
Working Capital Days
46
64
28
34
51
141
139
80
123
116
ROCE %
—
38%
34%
27%
33%
24%
21%
16%
20%
32%

Shareholding Pattern

As of Jun 2026
Promoters 32.66%
Public 21.72%
FIIs 21.61%
DIIs 19.56%
Others 4.44%
Government 0.01%
Total 100.00%
  Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024May 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
49.71%
41.05%
41.05%
41.05%
41.05%
39.41%
39.41%
39.41%
39.41%
38.93%
39.91%
39.91%
39.07%
35.98%
35.97%
35.96%
35.96%
32.66%
32.66%
32.66%
32.66%
32.66%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
7.16%
0.00%
8.97%
10.01%
12.92%
13.87%
15.52%
16.48%
16.94%
16.85%
16.67%
19.48%
21.61%
DIIs
0.00%
4.85%
2.63%
4.44%
3.01%
3.28%
3.72%
3.63%
5.23%
5.94%
5.55%
6.81%
8.81%
14.81%
19.93%
20.24%
18.31%
22.38%
22.59%
21.70%
19.60%
19.56%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
0.00%
42.98%
46.69%
44.74%
44.74%
38.35%
38.64%
38.96%
37.44%
36.13%
27.13%
30.01%
28.79%
26.06%
24.72%
23.56%
24.19%
23.27%
22.79%
23.53%
23.21%
21.72%
Others
50.29%
11.11%
9.62%
9.77%
11.19%
18.96%
18.23%
18.00%
17.92%
11.84%
27.41%
14.30%
13.33%
10.22%
5.51%
4.71%
5.05%
4.74%
5.10%
5.43%
5.03%
4.44%
No. of Shareholders
0
28
1,38,182
97,547
93,922
87,044
85,563
78,786
70,352
72,897
83,344
95,784
92,721
90,329
93,394
95,756
1,14,060
1,19,890
1,08,664
1,10,363
1,12,939
1,25,569

Documents

Frequently Asked Questions about Acutaas Chemicals Ltd

What does Acutaas Chemicals Ltd do?
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals...
Where is Acutaas Chemicals Ltd (ACUTAAS) listed?
Acutaas Chemicals Ltd is listed on the Indian stock exchanges. It is listed on NSE: ACUTAAS and BSE: 543349. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Acutaas Chemicals Ltd belong to?
Acutaas Chemicals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a market capitalisation of approximately ₹26304.37 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Acutaas Chemicals Ltd?
The Price-to-Earnings (PE) ratio of Acutaas Chemicals Ltd is 71.90. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Acutaas Chemicals Ltd?
Over the past 52 weeks, Acutaas Chemicals Ltd has traded between a low of ₹1,302 and a high of ₹3,740. This range helps investors understand the stock's price volatility and recent trading levels.
Does Acutaas Chemicals Ltd pay dividends?
Yes, Acutaas Chemicals Ltd has a dividend yield of 0.05%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a Return on Equity (ROE) of 12.15%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Acutaas Chemicals Ltd on Tapetide?
On Tapetide, you can view Acutaas Chemicals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Website amiorganics.com
CEO Mr. Nareshkumar Ramjibhai Patel
Employees 879
Listed 2021-09-14
Face Value ₹ 5
Issued Size 8,18,71,122

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List